Vaccines

Sabin Vaccine Development is focused on the development of sustainable and cost-effective vaccines for preventing diseases caused by two widespread neglected tropical diseases (NTDs)–– hookworm and schistosomiasis–– and malaria.

The Human Hookworm Vaccine Initiative (HHVI) is the world's first-ever vaccine initiative targeting human hookworm infection which would alleviate the suffering of more than a half-billion infected people. The Schistosomiasis Vaccine Initiative (SVI) was launched in 2008 to develop a vaccine for schistosomiasis which infects over 200 million people around the world and is the deadliest disease of the seven most prevalent NTDs, killing an estimated 280,000 people annually. Sabin Vaccine Development also formed a research collaboration with PATH Malaria Vaccine Initiative and the Johns Hopkins Bloomberg School of Public Health to aid in the development of a transmission-blocking malaria vaccine antigen through the Malaria Vaccine Program (MVP).